Drug Trial Radar · NCT02531438
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
Last checked: Nov 20, 2026Latest source record: Jan 16, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
774
Actual
Start
Nov 2015
Primary completion
Feb 5, 2017
Study completion Mar 10, 2017
Sponsor
- Lead sponsor
- Paratek Pharmaceuticals IncIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.
Conditions
- Bacterial Pneumonia
- Community-Acquired Infections
Interventions
OmadacyclineDrug
Injection for IV; Oral tablets
MoxifloxacinDrug
IV solution; Oral tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Early Clinical ResponseTime frame: Screening; 72 to 120 hours after the first dose of test article
Locations
140 sites in 25 countries. Site status is shown where the registry gives one.
Site 514
Birmingham, Alabama
Site 501
Mobile, Alabama
Site 508
Laguna Hills, California
Site 505
Ventura, California
Site 513
Stamford, Connecticut
Site 511
Zachary, Louisiana
Site 503
Detroit, Michigan
Site 520
Saint Paul, Minnesota
Site 512
St Louis, Missouri
Site 506
Buffalo, New York
Site 509
Dayton, Ohio
Site 516
Huntington, West Virginia
Site 220
Liège, Belgium
Site 276
Belo Horizonte, Minas Gerais, Brazil
Site 277
Passo Fundo, Rio Grande do Sul, Brazil
Site 274
Porto Alegre, Rio Grande do Sul, Brazil
Site 279
São José do Rio Preto, São Paulo, Brazil
Site 305
Kyustendil, Bulgaria
Site 303
Pernik, Bulgaria
Site 304
Plovdiv, Bulgaria
Site 306
Sliven, Bulgaria
Site 301
Sofia, Bulgaria
Site 302
Sofia, Bulgaria
Site 307
Sofia, Bulgaria
Site 250
Požega, Croatia
Site 205
Slavonski Brod, Croatia
Site 212
Zadar, Croatia
Site 201
Zagreb, Croatia
Site 202
Zagreb, Croatia
Site 203
Zagreb, Croatia
Site 251
Zagreb, Croatia
Site 405
Zagreb, Croatia
Site 412
Kyjov, Czechia
Site 410
Prague, Czechia
Site 411
Prague, Czechia
Site 414
Třebíč, Czechia
Site 390
Tbilisi, Georgia
Site 391
Tbilisi, Georgia
Site 392
Tbilisi, Georgia
Site 393
Tbilisi, Georgia
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.